Our Board of Directors

Lars Søren Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2013 Annual General Meeting. He chairs H. Lundbeck A/S’ Remuneration & Nomination Committee and is a member of H. Lundbeck A/S' Audit Committee. 

Lars Søren Rasmussen has considerable management experience in global med-tech. Lars Søren Rasmussen has most recently been CEO of Coloplast A/S from 2008 to 2018 and was a member of the company's executive management since 2001. During his time at Coloplast, Lars was responsible for various functions in the group, including global sales, innovation and production. He performed these duties from both Denmark and the US. Lars Rasmussen resigned his position as CEO of Coloplast A/S as of December 4, 2018 and took over the position as Chair of the Board of Directors of Coloplast A/S starting December 5. Lars Søren Rasmussen's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his top management experience and knowledge of efficiency improvements and internationalization. 

Lars Søren Rasmussen is Chair of the Board of Directors in Coloplast A/S and WS Audiology, Chair of the Danish Industry (DI) Committee on Diversity, Chair of the Danish Committee of Corporate Governance, Chair of the Think Tank Equalis and Chair of the Life Science Council under the Danish Ministry of Industry, Business and Financial Affairs. He also serves as member of the Board of Directors at Copenhagen University and at Gyldendal A/S.  

Lene Skole-Sørensen, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2015 Annual General Meeting. She is a member of H. Lundbeck A/S’ Remuneration & Nomination Committee and Scientific Committee.

Lene Skole-Sørensen is CEO at the Lundbeck Foundation, CEO at Lundbeckfond Invest A/S and Chair of the Board of Directors at LFI Equity A/S. Prior to joining the Lundbeck Foundation in 2014, Lene Skole-Sørensen was CFO at Coloplast A/S, where she was a member of the company’s executive management since joining in 2005. Lene Skole-Sørensen’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole-Sørensen held various positions in the AP Moller-Maersk group, most recently as CFO of Maersk Company Ltd., London from 2000-2005.

Lene Skole-Sørensen’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech. 

Lene Skole-Sørensen is Chair of the Board of Directors of Ørsted A/S and Deputy Chair of the Board of Directors of Falck A/S, ALK-Abelló A/S and Nordea Bank Abp.

Dr. Santiago Arroyo, MD and PhD, was born in June 1960 and is a US citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2021 Annual General Meeting and chairs H. Lundbeck's A/S' Scientific Committee.  

Dr. Arroyo has more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology.

In 2003, Dr. Arroyo joined the pharmaceutical industry and has held a variety of positions in clinical research and development - most recently as Chief Development Officer at Bicycle Therapeutics. Prior to this, Dr. Arroyo served as Chief Medical Officer at Fulcrum Therapeutics and Momenta Pharmaceuticals. Before that, he held roles of Senior Vice President, Head of Clinical Research, and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., Therapeutic Area Head for Neurosciences, Discovery Medicine, and Clinical Pharmacology at Bristol-Myers Squibb, and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development.

Dr. Arroyo’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his therapeutic and deep scientific expertise in neuroscience and beyond as well as strategic and business vision. 

Santiago Arroyo serves as a member of the Board of Directors at GlycoEra AG, Switzerland.

Jeffrey Berkowitz, Juris Doctor and BA in Political Science, was born on 9 January 1966 and is a US citizen. He was nominated for election to the H. Lundbeck A/S’ Board of Directors at the 2018 Annual General Meeting and is a member of H. Lundbeck A/S' Scientific Committee and since March 2019 a member of the Remuneration & Nomination Committee.

Jeffrey Berkowitz is currently the CEO of Real Endpoints, a leader in the development and implementation of proprietary tools to strengthen market access for biopharmaceutical companies. Prior to this, Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as an Executive Committee member and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2014 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co, then as President of Walgreens Boots Alliance Development in the period 2010 to 2015. From 1998 to 2010, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.

Jeffrey Berkowitz’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven results and global experience with payers, pharmaceutical companies, specialty and retail pharmacies and drug distributors with deep experience in generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy distribution and health care strategies. He is a sought after thought leader and speaker in the area of pharmaceutical market access and reimbursement and has extensive public board and committee experience.

Jeffrey Berkowitz is Chair of the Board of PharmaTwoB. He is also a member of the Boards of Directors of Zealand Pharma A/S and Click Therapeutics. 

Lars Holmqvist, MSc in Business Administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2015 Annual General Meeting. He is a member of H. Lundbeck A/S' Audit Committee.

Lars Holmqvist was senior advisor within healthcare at Bain Capital Private Equity. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Inc, DAKO A/S and Agilent Technologies.

Lars Holmqvist’s special qualifications for serving on H. Lundbeck A/S' Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.

Lars Holmqvist is Chair of the Board of Directors for Biovica International AB and a member of the Boards of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Vitrolife AB, and Life Healthcare.

Jakob Riis holds a Master's degree in Forestry and PhD in Econometrics from The Royal Veterinary and Agricultural University. He was born in 1966 and is a Danish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2023 Annual General Meeting. He is a member of H. Lundbeck A/S' Scientific Committee.

Jakob Riis is currently the CEO at Falck A/S and is considered as non-independent Lundbeck Board member, as the Lundbeck Foundation is a significant shareholder in the company. 

Jakob Riis has more than 25 years of experience in management and sales & marketing in the international healthcare industry. He previously worked at Novo Nordisk for 20 years in various positions in the commercial area (U.S. sales organization, Japan, Head of Marketing for more than a decade, and most recent as President of the North American business, member of the Executive Management). 

Jakob’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven track record in pharmaceutical value chain management from early-stage assets, production planning, registration trials, label negotiations, market access and global commercialization. In addition, he has extensive experience in operating in a listed company and market communication. 

Jakob Riis currently serves as Chair of the Board of Directors in Falck Healthcare A/S and Response A/S. He is also a member of the Board of Directors of the Danish Chamber of Commerce and Falck Danmark A/S. Furthermore, Jakob Riis is currently the CEO of Falck Danmark A/S and Adelca ApS.

Dorothea Wenzel holds a PhD in Health Economics & Macroeconomics and a M.Sc. in Business & Computer Sciences from the University of Darmstadt in Germany. She has also held fellowships at Harvard and was a visiting student at the University of California at Berkley. Dorothea Wenzel was born on 16 April 1969 and is a German citizen. She was nominated for election to H. Lundbeck A/S' Board of Directors at the 2021 Annual General Meeting. She chairs H. Lundbeck A/S' Audit Committee. 

Dorothea Wenzel is an independent Board member. She had a long career at Merck KGaA, headquartered in Darmstadt, Germany, where she most recently until August 2021 served as Executive Vice President and Head of the Global Business Unit Surface Solutions. In 2018 she was the CFO & Head of Strategy of the Performance Materials Division, from 2014 to 2018 she headed Merck’s Global Fertility Business Franchise, and from 2005 to 2013 she was the CFO of Merck’s Healthcare division. Prior to Merck she worked at McKinsey & Comp., with an e-commerce startup and for a German governmental commission.

Dorothea's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include an impressive track record in Finance and Strategy leadership across multiple industries. Dorothea further strengthens the Board's competencies in finance and business transformation to ensure the company remains best set for the future. 

Dorothea Wenzel is a member of the Board of Directors of Dentsply Sirona Inc., a member of the Supervisory Board (Chair of Audit Committee) at Servier Pharmaceuticals and a member of the supervisory board of Gerresheimer AG.

Camilla Gram Andersson, M.Sc. in civil engineering, was born in 1972 and is a Danish citizen.

She has been employed at Lundbeck since 2005 and currently heads up Corporate Health, Safety & Environment (HSE) department, where she is responsible for the development of Lundbeck’s HSE strategy.

Camilla is a member of the Industrial Sectorial Board of Occupational Health and Safety (DI) and Specialized Committee of Chemistry (DI) as well as a member of the EHS expert group in European Federation of Pharmaceutical Industries and Associations (EFPIA).

Hossein Armandi, Process Technologist, was born in 1962 and is a Danish citizen. He has been employed at Lundbeck since 1995, holds a position as Research Technician and currently works in the research department of Translational Drug Metabolism and Pharmacokinetics.

Dorte Clausen, M.Sc. Molecular Biomedicine, was born in 1984 and is a Danish citizen. She has been employed at Lundbeck since 2012. She currently manages clinical studies within psychiatry and holds a position as Clinical Trial Manager, Specialist.

Dorte is a member of the Board at a Danish Union Pharmadanmark as well as a member of the Board at Training & Conference Center Pharmakon.

Lasse Skibsbye, Pharmacist and PhD in Medicine with specialty in cardiovascular safety pharmacology, was born in 1983 and is a Danish citizen.

He has been employed at Lundbeck since 2016 and currently holds a position as Principal Scientist and Safety Pharmacologist in the department of Exploratory Toxicology, Non-clinical Safety Research.

Lasse is a member of the Board in Safety Pharmacology Society.